5 - Contents

6-7 NEWS
GSK acquires Sierra Oncology for £1.5bn; FDA fast-tracks Alzheimer's therapy

8-9 NEWS
New insights into Alzheimer’s disease; EFPIA pledges to boost EU drug access

10-11 CORONAVIRUS NEWS
AZ’s Evusheld reduces risk of symptomatic COVID-19; COVAX gains united support

12 DARWIN'S MEDICINE
Your market waves flags, if you know where to look

13 POLICY AND PUBLIC HEALTH
Will that be cash or charge: India asks its people to pay for COVID-19 booster shots

14 WALKING IN THEIR SHOES
Having a chronic disease for a day

15 PHARMA MARKETERS' BLOG
Asking better questions to inform a stronger strategy

16-17 BUILDING A RESILIENT CLINICAL DEVELOPMENT STRATEGY - WHEN LOCAL EVENTS HAVE A GLOBAL IMPACT
Phesi's Paul Chew talks about how a clinical trial is only as strong as its weakest link and that, all too often, we are seeing research into life-changing medicines being delayed due to world events

20-21 ACCELERATING THERAPAUTIC DISCOVERY AND DEVELOPMENT
Biotech innovation played a crucial role in the fight against COVID-19, but there is more that can be done to accelerate biotech innovation across other segments and applications

40-41 ALZHEIMER’S DISEASE: THE CHALLENGES FACING NEW DRUG TREATMENTS LIKE ADUHELM
Alzheimer’s currently affects around 900,000 people in the UK and there are an estimated 54 million people globally who have some form of dementi

22-31 COMMUNICATION EXCELLENCE
Two years after the start of the coronavirus pandemic, we look at the continued impact of the global healthcare crisis and how it has pushed healthcare communications firmly into the digital age

32-34 BEHAVIOUR CHANGE - A MAZE OF DECISIONS
How we can use behaviour change to sharpen the impact of cutting edge science to power benefits for patients and industry

38-39 BUILDING A MAGNET FOR TALENT
How Sanofi China is shifting its business focus from talent retention to nurturing and developing its employees

45 HEALTHCARE COMMS
Langland teams with mental health charity Mind; Fishawack acquires Policy Analysis Inc

46 PEOPLE
Q&A with Matt de Gruchy

May 2022